Notice on Convening the 3rd Extraordinary General Meeting in 2024
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Notice on Convening the 3rd Extraordinary General Meeting in 2024
Filed with SSE · · 6 pages · Chinese
Release
Sinocelltech Group Limited on 6ix
Earlier from Sinocelltech
- Announcement on Convening the Q3 2024 Performance Briefing
- Report for Q3 2024
- Announcement on the Company's Voluntary Disclosure of Approval Notice for the Clinical Trial of Recombinant Respiratory Syncytial Virus Vaccine SCTV02 by the Company's Holding Subsidiary
- Announcement on Resolution of the 2nd Extraordinary General Meeting in 2024
- Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of Holding Subsidiary's Recombinant Shingles Vaccine SCTV04C
Later from Sinocelltech
- Announcement on the Addition of New Office Address and Change of Investor Contact Phone Number
- Announcement on Resolution of the 3rd Extraordinary General Meeting in 2024
- Announcement on Expected Gains in Annual Performance for 2024
- Announcement on Preliminary Earnings Estimate for 2024
- Announcement on Voluntary Disclosure of Drug Registration Certificate Obtained by Holding Subsidiary
Follow Sinocelltech into a list and get an email when it puts out news.
Follow Sinocelltech